|
|
5 April 2018 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 29 March 2018 that on the same day, Penny Freer, who is a Director, had sold 13,888 Ordinary Shares of 5p held in her name at a price of 318.60p per Ordinary Share. On the same day, Penny Freer also purchased 13,888 Ordinary Shares of 5p through a self-invested personal pension (“SIPP”) held in her name at a price of 318.80p per Ordinary Share.
The number of shares held by Penny Freer and the beneficial ownership of the shares remains unchanged. Both transactions are part of normalised tax planning.
The transactions are summarised below:
|
Director |
Number of Ordinary Shares sold from Penny Freer |
Price per Ordinary Share sold |
Number of Ordinary Shares purchased by SIPP |
Price paid per Ordinary Share by SIPP |
|
Penny Freer |
13,888 |
318.60p |
13,888 |
318.80p |
Advanced Medical Solutions Group plc also announces that it was notified on 4 April 2018 that on the same day, Chris Meredith, who is a Director and PDMR, had sold 10,500 Ordinary Shares of 5p held in the name of Platform Securities Nominees Limited (“Nominee”) at a price of 310.20p per Ordinary Share.
On the same day, Chris Meredith purchased 2,568 Ordinary Shares of 5p through a self-invested personal pension (“SIPP”) held in his name at a price of 310.50p per Ordinary Share. The Company was also informed that at the same time Individual Savings Accounts (“ISA’s”) held in the name of Chris Meredith’s PCA’s purchased 4,095 Ordinary Shares of 5p at a price of 310.50p per Ordinary Share and that Lifetime Individual Savings Accounts (“LISA’s”) held in the name of Chris Meredith’s PCA’s purchased 3,837 Ordinary Shares of 5p at a price of 310.50p per Ordinary Share.
The number of shares, and the beneficial ownership of the shares, held by Chris Meredith and his PCA’s remains unchanged. These transactions are part of normalised tax planning.
The transactions are summarised below:
|
Director |
Number of Ordinary Shares sold from Nominee |
Price per Ordinary Share sold |
Number of Ordinary Shares purchased by SIPP |
Price paid per Ordinary Share by SIPP |
Number of Ordinary Shares purchased by ISA’s |
Price paid per Ordinary Share by ISA’s |
Number of Ordinary Shares purchased by LISA’s |
Price paid per Ordinary Share by LISA’s |
|
Chris Meredith |
2,568 |
310.20p |
2,568 |
310.50p |
– |
– |
– |
– |
|
Chris Meredith |
4,095 |
310.20p |
– |
– |
4,095 |
310.50p |
– |
– |
|
Chris Meredith |
3,837 |
310.20p |
– |
– |
– |
– |
3,837 |
310.50p |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Penny Freer |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 13,888 Ordinary Shares of 5p held in the name of Penny Freer · Purchase of 13,888 Ordinary Shares of 5p by a SIPP held in the name of Penny Freer |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 13,888 Aggregated price: 318.60p |
||||||
|
e) |
Date of the transaction: 29/03/2018 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 2,568 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 2,568 Ordinary Shares of 5p by a SIPP held in the name of Chris Meredith
|
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 2,568 Aggregated price: 310.20p |
||||||
|
e) |
Date of the transaction: 04/04/2018 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 4,095 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 4,095 Ordinary Shares of 5p into ISA’s held in the name of Chris Meredith’s PCA’s
|
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 4,095 Aggregated price: 310.20p |
||||||
|
e) |
Date of the transaction: 04/04/2018 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 3,837 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 3,837 Ordinary Shares of 5p into a LISA’s held in the name of Chris Meredith’s PCA’s
|
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 3,837 Aggregated price: 310.20p |
||||||
|
e) |
Date of the transaction: 04/04/2018 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
– End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Philippa Gardner |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb / Gary Clarence |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. . For more information, please see www.admedsol.com.
This information is provided by RNS
END
DSHBLGDSUSGBGIU